A study was conducted using a diabetic mouse model - a recognised, and widely used, animal model of delayed wound healing - and performed at an internationally recognized reference lab. The healing response of wounds treated was compared against human growth factors as positive control.
The healing progress exceeded initial expectations with over 90% wound closure after only 16 days. The results prove to be very encouraging and is seen as a major achievement both by the company and experts in the field. With these obtained results Biovotec is now entering the phase of final product formulation for human trials with the aim to become the standard care for ‘delayed healing wounds’.
I'm busy working on my blog posts. Watch this space!